Regeneron Pharmaceuticals (REGN) Stock: Gaining Big On Earnings


Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company reported its fourth quarter results, blowing away expectations and leading to excitement among investors. Today, we’ll talk about what we saw from earnings, what we’re seeing from the stock as a result, and what we’ll be watching for ahead.

REGN Reports Strong Earnings 

As mentioned above, Regeneron is having an overwhelmingly strong start to the trading session this morning after reporting its financial results for the fourth quarter. Here’s what we saw from the report:

  • Adjusted Earnings Per Share – In terms of earnings per share, REGN did overwhelmingly well. During the fourth quarter, analysts expected that the company would generate earnings in the amount of $4.68 per share. However, on the earnings report, investors learned that earnings came in at $5.23 per share. Not only did that figure beat expectations, it showed strong year over year growth from $3.04 per share in the same quarter one year ago.
  • Revenue – Revenue also proved to be a big hit for REGN. During the quarter, it was expected that the company would generate revenue in the amount of $1.5 billion. However, the company actually reported revenue in the amount of $1.58 billion. This figure also showed strong year over year growth. In the same quarter of 2016, the company reported revenue in the amount of $1.23 billion.

In a statement, Leonard S. Schleifer, M.D., Ph.D., President and CEO at Regeneron, had the following to offer:

In 2017, Regeneron’s core EYLEA business continued to grow and we diversified our revenue stream by bringing two new products to patients in need… We are anticipating additional pipeline progress in 2018, including regulatory decisions for dupilumab in uncontrolled asthma and cemiplimab in advanced cutaneous squamous cell carcinoma, cardiovascular outcomes data for Praluent, as well as Phase 3 data for EYLEA in diabetic retinopathy. 

What We’re Seeing From The Stock 

As investors, one of the first lessons that we learn is that the news moves the market. In this particular case, the news proved to be overwhelmingly positive. After all, a beat on earnings and revenue is always a good thing. As a result, it’s no surprise to see strong gains in the value of Regeneron Pharmaceuticals. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:07), REGN is trading at $344.00 per share after a gain of $9.39 per share or 2.81% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on REGN. In particular, we’re interested in following the ongoing development of the company’s robust pipeline as well as continued sales growth of their already commercially approved products. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

Previous articleWill India Actually Ban Cryptocurrency?
Next articleNXT-ID (NXTD) Stock: Gaining Big On Gains On Flip
Hey, Im Joshua, the founder of CNA Finance. I enjoy following the trends in the market and finding the catalysts that are making the moves. If you want to get in contact with me, leave a comment below or email me at Please keep in mind that I am not an investment advisor and nor is CNA Finance. This is a news and information gathering outlet. We may work directly with some of the companies that we write about. If we have a business relationship with an issuer, we will mention that in the articles. We also have various affiliate relationships with advertisers and may be paid if you sign up for a service that you were referred to through our website.


Please enter your comment!
Please enter your name here